Pharmaceutical News

RSS

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group, one of India's leading generic pharmaceutical companies and one of the world's largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India.

5 Aug 2015

Positive, nonconfrontational approach can convince parents to vaccinate their children

Many people who are skeptical about vaccinating their children can be convinced to do so, but only if the argument is presented in a certain way, a team of psychologists from UCLA and the University of Illinois at Urbana-Champaign reported today.

5 Aug 2015

Non-surgical approach to treating 'double chins'

UT Southwestern Medical Center plastic surgeons have a non-surgical approach to treating "double chins" − the moderate-to-severe fat below the chin using an FDA-approved drug that when injected into tissue destroys fat cells.

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Lenalidomide therapy may have immediate effect in treatment of sarcoidosis-related symptoms

A case study published in the August issue of the journal CHEST found lenalidomide treatments may have an immediate effect in the treatment of sarcoidosis-related symptoms. Sarcoidosis, a disease that involves abnormal collections of inflammatory cells that can form nodules in various organs, can affect individuals from all racial and age groups.

5 Aug 2015

Nonmedical use of prescription opioids increasing among young adults

The nonmedical use of prescription opioids (POs) has become an area of increasing public health concern in the United States and rates of use are particularly high among young adults. In the past decade, an emerging "epidemic" of nonmedical PO use has been reported.

5 Aug 2015

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Researchers have packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness at destroying tumors.

5 Aug 2015

Par Pharmaceutical starts shipment of generic version of Sodium Edecrin

Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg.

4 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.

4 Aug 2015

Cipher receives Acceptance Review Notification from FDA for 510(k) submission for Dermadexin

Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.

4 Aug 2015

Benefits and risks of taking antidepressant medications during pregnancy

Treating maternal psychiatric disorder with commonly used antidepressants is associated with a lower risk of certain pregnancy complications including preterm birth and delivery by Caesarean section, according to researchers at Columbia University's Mailman School of Public Health, Columbia University Medical Center, and the New York State Psychiatric Institute. However, the medications -- selective serotonin reuptake inhibitors, or SSRIs -- resulted in an increased risk of neonatal problems.

4 Aug 2015

People with chronic insomnia may be able to get relief from half of standard sleeping pills

The roughly nine million Americans who rely on prescription sleeping pills to treat chronic insomnia may be able to get relief from as little as half of the drugs, and may even be helped by taking placebos in the treatment plan, according to new research published today in the journal Sleep Medicine by researchers from the Perelman School of Medicine at the University of Pennsylvania.

4 Aug 2015

Penn Medicine devises new approach to develop vaccines against lethal diseases

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination.

4 Aug 2015

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery.

4 Aug 2015

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain.

3 Aug 2015

Pharmaceutical News

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Positive, nonconfrontational approach can convince parents to vaccinate their children

Non-surgical approach to treating 'double chins'

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Lenalidomide therapy may have immediate effect in treatment of sarcoidosis-related symptoms

Nonmedical use of prescription opioids increasing among young adults

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Par Pharmaceutical starts shipment of generic version of Sodium Edecrin

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Cipher receives Acceptance Review Notification from FDA for 510(k) submission for Dermadexin

Benefits and risks of taking antidepressant medications during pregnancy

People with chronic insomnia may be able to get relief from half of standard sleeping pills

Penn Medicine devises new approach to develop vaccines against lethal diseases

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

Omeros receives EC approval to market Omidria in EU and other European countries

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Anti-dementia drugs could result in harmful weight loss, say researchers

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

Research shows specific routes of administration can predict risk of drug addiction

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News